389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors

• Laura Carter,
• Andrea Wang-Gillam,
• Johanna Bendell,
• Wungki Park,
• Wells Messersmith,
• Drew Rasco,
• Lei Zhou,
• Jean-Marie Bruey,
• Beatrice Ferguson,
• Jakob Dupont,
• Marya Chaney,
• Johann De Bono,
• David Nickle,
• Anna Galkin

Affiliations

Laura Carter

6Gossamer Bio, Inc., San Diego, CA, USA

Andrea Wang-Gillam

4Washington University School of Medicine, St. Louis, MO, USA

Johanna Bendell

8Sarah Cannon/Tennessee Oncology, Nashville, TN, USA

Wungki Park

5Memorial Sloan Kettering Cancer Center, New York, NY, USA

Wells Messersmith

1University of Colorado School of Medicin, Aurora, CO, USA

Drew Rasco

2The START Center for Cancer Care, San Antonio, TX, USA

Lei Zhou

6Gossamer Bio, Inc., San Diego, CA, USA

Jean-Marie Bruey

6Gossamer Bio, Inc., San Diego, CA, USA

Beatrice Ferguson

6Gossamer Bio, Inc., San Diego, CA, USA

Jakob Dupont

6Gossamer Bio, Inc., San Diego, CA, USA

Marya Chaney

7Merck and Co, Inc., Kenilworth, NJ, USA

Johann De Bono

3The ICR and Royal Marsden, London, UK

David Nickle

6Gossamer Bio, Inc., San Diego, CA, USA

Anna Galkin

6Gossamer Bio, Inc., San Diego, CA, USA